DaShenLin Pharmaceutical Group Co., Ltd. (SHA:603233)

China · Delayed Price · Currency is CNY

19.82

+0.15 (0.76%)

Mar 6, 2026, 3:00 PM CST

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Retail	21.91B	20.49B	19.24B	15.28B	13.77B
Retail Growth	6.89%	6.50%	25.89%	10.99%	-
Franchise and Distribution	3.94B	3.42B	1.54B	1.01B	490.54M
Franchise and Distribution Growth	15.12%	122.46%	52.79%	105.29%	-
Other Operations	616.51M	589.44M	444.11M	446.56M	304.97M
Other Operations Growth	4.59%	32.72%	-0.55%	46.43%	-
Total	26.46B	24.51B	21.22B	16.74B	14.57B
Total Growth	7.99%	15.46%	26.80%	14.90%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
China	26.50B	24.53B	21.25B	16.76B	14.58B
China Growth	8.01%	15.45%	26.78%	14.92%	30.89%
Total	26.50B	24.53B	21.25B	16.76B	14.58B
Total Growth	8.01%	15.45%	26.78%	14.92%	30.89%

Source: S&P Global Market Intelligence.